Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS), also widely known as ciRS-7, is a highly conserved, brain-abundant circular RNA (circRNA) that acts as a natural "super sponge" for microRNA-7 (miR-7). It contains over 70 binding sites for miR-7, thereby sequestering this microRNA and preventing it from suppressing its target mRNAs, which are involved in critical pathways like EGFR/RAF1 and PI3K/AKT. Consequently, dysregulation of CDR1-AS is heavily implicated in various human pathologies.
In oncology, CDR1-AS is frequently overexpressed and functions as an oncogene, promoting cell proliferation, invasion, and metastasis, as well as contributing to chemoresistance in solid tumors such as colorectal, lung, and breast cancers. Conversely, its downregulation is associated with neurodegenerative disorders like Alzheimer's disease, where its loss leads to elevated miR-7 levels and subsequent downregulation of protective target genes. While no FDA-approved drugs currently target CDR1-AS, it represents a highly promising therapeutic target and diagnostic biomarker. Preclinical strategies under investigation include the use of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and CRISPR/Cas9 systems to modulate its expression and restore normal microRNA regulatory networks.
Antisense knockdown or RNA interference to inhibit microRNA sponging activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS).